Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9vHPV Vaccine Immunogenicity and Safety in Japanese Boys and Girls
NCT04772534Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co.. Started May 2021; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04772534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772534.